Item Type | Name |
Concept
|
Aminolevulinic Acid
|
Concept
|
Age Factors
|
Concept
|
Antibody-Dependent Cell Cytotoxicity
|
Concept
|
Antigen-Presenting Cells
|
Concept
|
American Cancer Society
|
Concept
|
Aftercare
|
Concept
|
Blood Pressure
|
Concept
|
Antibody Formation
|
Concept
|
Carcinoma, Papillary
|
Concept
|
Carcinoma, Squamous Cell
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
Concept
|
Calcitonin
|
Concept
|
Analysis of Variance
|
Concept
|
Antibodies, Monoclonal
|
Concept
|
Histocompatibility Antigens Class II
|
Concept
|
Benzazepines
|
Concept
|
Biological Availability
|
Concept
|
Bayes Theorem
|
Concept
|
Carcinoma, Renal Cell
|
Concept
|
Bibenzyls
|
Concept
|
Drug Packaging
|
Concept
|
Biopsy, Needle
|
Concept
|
Biopsy
|
Concept
|
Urinary Bladder Neoplasms
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
Concept
|
Cell Division
|
Concept
|
Cell Cycle
|
Concept
|
Cell Transformation, Neoplastic
|
Concept
|
Chromosome Deletion
|
Concept
|
Cisplatin
|
Concept
|
Clinical Competence
|
Concept
|
DNA-Binding Proteins
|
Concept
|
Drug Synergism
|
Concept
|
Interviews as Topic
|
Concept
|
Decision Support Techniques
|
Concept
|
Dose-Response Relationship, Radiation
|
Concept
|
DNA Mutational Analysis
|
Concept
|
Kidney Neoplasms
|
Concept
|
Epithelial Cells
|
Concept
|
Deglutition Disorders
|
Concept
|
Dental Caries
|
Concept
|
Clinical Protocols
|
Concept
|
Mass Screening
|
Concept
|
Erythropoietin
|
Concept
|
Double-Blind Method
|
Concept
|
Drug Interactions
|
Concept
|
Infant, Newborn
|
Concept
|
Insulin-Like Growth Factor II
|
Concept
|
Fluorouracil
|
Concept
|
Decision Making
|
Concept
|
Feasibility Studies
|
Concept
|
Killer Cells, Natural
|
Concept
|
Osteoradionecrosis
|
Concept
|
Coloring Agents
|
Concept
|
Dose-Response Relationship, Drug
|
Concept
|
Drug Labeling
|
Concept
|
Laryngeal Neoplasms
|
Concept
|
Insulin-Like Growth Factor I
|
Concept
|
Peer Review
|
Concept
|
Hospitalization
|
Concept
|
Light
|
Concept
|
Medicare
|
Concept
|
Macrophages
|
Concept
|
Membrane Proteins
|
Concept
|
Metformin
|
Concept
|
Microfilament Proteins
|
Concept
|
Pharmacogenetics
|
Concept
|
Pilot Projects
|
Concept
|
Pneumonia, Aspiration
|
Concept
|
Immunohistochemistry
|
Concept
|
Oropharyngeal Neoplasms
|
Concept
|
Palliative Care
|
Concept
|
Methotrexate
|
Concept
|
Mouthwashes
|
Concept
|
Health Promotion
|
Concept
|
Hot Temperature
|
Concept
|
HeLa Cells
|
Concept
|
Review Literature as Topic
|
Concept
|
Internship and Residency
|
Concept
|
Neoplasm Staging
|
Concept
|
Periodontitis
|
Concept
|
Phosphorylcholine
|
Concept
|
Lung Neoplasms
|
Concept
|
Phenylurea Compounds
|
Concept
|
Phosphorylation
|
Concept
|
Osteonecrosis
|
Concept
|
Taste Disorders
|
Concept
|
Probability
|
Concept
|
Population Surveillance
|
Concept
|
Preoperative Care
|
Concept
|
Protein-Tyrosine Kinases
|
Concept
|
Proto-Oncogene Proteins
|
Concept
|
Transcription Factors
|
Concept
|
Immunoglobulin G
|
Concept
|
Rats, Inbred F344
|
Concept
|
Regression Analysis
|
Concept
|
Guanine
|
Concept
|
Referral and Consultation
|
Concept
|
Registries
|
Concept
|
Postoperative Period
|
Concept
|
Risk Factors
|
Concept
|
Salivary Gland Neoplasms
|
Concept
|
Quality of Life
|
Concept
|
Radiation Dosage
|
Concept
|
Radiation Tolerance
|
Concept
|
Radiography
|
Concept
|
Radiotherapy Planning, Computer-Assisted
|
Concept
|
RNA, Viral
|
Concept
|
ROC Curve
|
Concept
|
Cohort Studies
|
Concept
|
Radiodermatitis
|
Concept
|
Research
|
Concept
|
Rimantadine
|
Concept
|
Sensitivity and Specificity
|
Concept
|
Sexual Partners
|
Concept
|
Tomography, X-Ray Computed
|
Concept
|
Thalidomide
|
Concept
|
United States Food and Drug Administration
|
Concept
|
Survival
|
Concept
|
Clinical Trials, Phase I as Topic
|
Concept
|
Practice Guidelines as Topic
|
Concept
|
Receptors, IgG
|
Concept
|
Iodine Radioisotopes
|
Concept
|
Isotretinoin
|
Concept
|
Licensure
|
Concept
|
Herpesvirus 1, Human
|
Concept
|
Proportional Hazards Models
|
Concept
|
Randomized Controlled Trials as Topic
|
Concept
|
Risk Assessment
|
Concept
|
Drug Resistance, Neoplasm
|
Concept
|
Radiopharmaceuticals
|
Concept
|
Reverse Transcriptase Polymerase Chain Reaction
|
Concept
|
Trismus
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Mitogen-Activated Protein Kinases
|
Concept
|
NF-kappa B
|
Concept
|
Osteonectin
|
Concept
|
Metabolic Clearance Rate
|
Concept
|
Lymphatic Metastasis
|
Concept
|
Program Evaluation
|
Concept
|
Paclitaxel
|
Concept
|
Comorbidity
|
Concept
|
Clinical Trials, Phase II as Topic
|
Concept
|
Case-Control Studies
|
Concept
|
RNA Interference
|
Concept
|
In Situ Hybridization
|
Concept
|
Protein Structure, Tertiary
|
Concept
|
Treatment Outcome
|
Concept
|
Neoplasm Metastasis
|
Concept
|
Neoplasm Recurrence, Local
|
Concept
|
Interferon-alpha
|
Concept
|
Antigen Presentation
|
Concept
|
Photosensitizing Agents
|
Concept
|
Gene Deletion
|
Concept
|
Platinum Compounds
|
Concept
|
Receptors, Growth Factor
|
Concept
|
Cell Proliferation
|
Concept
|
ras Proteins
|
Concept
|
Angiogenesis Inhibitors
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
Concept
|
Cross-Over Studies
|
Concept
|
Gene Knockout Techniques
|
Concept
|
In Situ Hybridization, Fluorescence
|
Concept
|
Receptor, ErbB-3
|
Concept
|
Self Report
|
Concept
|
Collagen Type I
|
Concept
|
Oncogene Proteins, Viral
|
Concept
|
Organ Preservation
|
Concept
|
Chemoradiotherapy, Adjuvant
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
Concept
|
B7-H1 Antigen
|
Concept
|
Consensus
|
Concept
|
Positron-Emission Tomography
|
Concept
|
Radiotherapy, Intensity-Modulated
|
Concept
|
Proteomics
|
Concept
|
Hypoxia-Inducible Factor 1, alpha Subunit
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
Concept
|
Carcinoma, Large Cell
|
Concept
|
Area Under Curve
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p16
|
Concept
|
Proto-Oncogene Proteins B-raf
|
Concept
|
Cell Growth Processes
|
Concept
|
Cell Cycle Proteins
|
Concept
|
Transcription Factor AP-1
|
Concept
|
Proto-Oncogene Proteins c-kit
|
Concept
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
Concept
|
Quality-Adjusted Life Years
|
Concept
|
Sirolimus
|
Concept
|
STAT3 Transcription Factor
|
Concept
|
Proto-Oncogene Proteins c-ret
|
Concept
|
Photochemotherapy
|
Concept
|
Platinum
|
Concept
|
Placebos
|
Concept
|
Prognosis
|
Concept
|
Publishing
|
Concept
|
Mucositis
|
Concept
|
Protein Kinase C
|
Concept
|
Quinazolines
|
Concept
|
Pyrimidinones
|
Concept
|
Surveys and Questionnaires
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Severity of Illness Index
|
Concept
|
Research Design
|
Concept
|
RNA, Messenger
|
Concept
|
Vascular Endothelial Growth Factor Receptor-3
|
Concept
|
Sleep Apnea Syndromes
|
Concept
|
Sleep Wake Disorders
|
Concept
|
Stomach Neoplasms
|
Concept
|
Structure-Activity Relationship
|
Concept
|
Sulfonamides
|
Concept
|
Biomedical Research
|
Concept
|
Tissue Distribution
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
Concept
|
HEK293 Cells
|
Concept
|
Rats
|
Concept
|
SOX9 Transcription Factor
|
Concept
|
Cyclin D
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
Concept
|
TOR Serine-Threonine Kinases
|
Concept
|
Supraglottitis
|
Concept
|
Antibodies, Monoclonal, Humanized
|
Concept
|
CTLA-4 Antigen
|
Concept
|
Sex Factors
|
Concept
|
Adaptor Proteins, Signal Transducing
|
Concept
|
Temperature
|
Concept
|
Down-Regulation
|
Concept
|
Hypoxia-Inducible Factor 1
|
Concept
|
Multivariate Analysis
|
Concept
|
Survival Analysis
|
Concept
|
Transforming Growth Factor alpha
|
Concept
|
Cyclins
|
Concept
|
DNA Copy Number Variations
|
Concept
|
Transfection
|
Concept
|
Confidence Intervals
|
Concept
|
Receptors, Cytokine
|
Concept
|
Odds Ratio
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
Concept
|
Food-Drug Interactions
|
Concept
|
Receptor, ErbB-2
|
Concept
|
Clinical Trials, Phase III as Topic
|
Concept
|
Proto-Oncogene Proteins c-met
|
Concept
|
Cyclin E
|
Concept
|
SEER Program
|
Concept
|
Statistics, Nonparametric
|
Concept
|
Models, Economic
|
Concept
|
HSP90 Heat-Shock Proteins
|
Concept
|
CCAAT-Enhancer-Binding Protein-beta
|
Concept
|
Nomograms
|
Concept
|
Toll-Like Receptor 7
|
Concept
|
Genome-Wide Association Study
|
Concept
|
Precision Medicine
|
Concept
|
RNA, Small Interfering
|
Concept
|
Qualitative Research
|
Concept
|
Pain Management
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
Concept
|
Vascular Endothelial Growth Factor A
|
Concept
|
Programmed Cell Death 1 Receptor
|
Concept
|
Cell Line, Tumor
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
Concept
|
Toll-Like Receptor 9
|
Concept
|
Protein Kinase C-alpha
|
Concept
|
Kaplan-Meier Estimate
|
Concept
|
Class Ib Phosphatidylinositol 3-Kinase
|
Concept
|
Standard of Care
|
Concept
|
Neoplasm Grading
|
Concept
|
Immunotoxins
|
Concept
|
Carcinoembryonic Antigen
|
Concept
|
Carrier Proteins
|
Concept
|
Cell Line
|
Concept
|
Cell Survival
|
Concept
|
Cells, Cultured
|
Concept
|
Clinical Trials as Topic
|
Concept
|
Cotinine
|
Concept
|
Deoxycytidine
|
Concept
|
Epidermal Growth Factor
|
Concept
|
Follow-Up Studies
|
Concept
|
Hypopharyngeal Neoplasms
|
Concept
|
Nasopharyngeal Neoplasms
|
Concept
|
Neoplasm Invasiveness
|
Concept
|
Neoplasm Proteins
|
Concept
|
Niacinamide
|
Concept
|
Nuclear Proteins
|
Concept
|
Predictive Value of Tests
|
Concept
|
Prospective Studies
|
Concept
|
Proto-Oncogenes
|
Concept
|
Pyridones
|
Concept
|
Retrospective Studies
|
Concept
|
Tolonium Chloride
|
Concept
|
Tumor Suppressor Protein p53
|
Concept
|
Oligonucleotides, Antisense
|
Concept
|
Anticarcinogenic Agents
|
Concept
|
Focus Groups
|
Concept
|
Sequence Analysis, RNA
|
Concept
|
DNA Primers
|
Concept
|
Disease-Free Survival
|
Concept
|
Cyclin D1
|
Concept
|
Polymorphism, Single Nucleotide
|
Concept
|
MicroRNAs
|
Concept
|
Vascular Endothelial Growth Factor Receptor-1
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
p38 Mitogen-Activated Protein Kinases
|
Concept
|
Proto-Oncogene Proteins c-akt
|
Academic Article
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
Academic Article
|
Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
|
Academic Article
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
Academic Article
|
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
|
Academic Article
|
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
|
Academic Article
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
Academic Article
|
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
|
Academic Article
|
The expanding role of systemic therapy in head and neck cancer.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle.
|
Academic Article
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
Academic Article
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
Academic Article
|
Personalizing cancer care: updates on head and neck cancer.
|
Academic Article
|
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.
|
Academic Article
|
[18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality.
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
Academic Article
|
Airway management before chemoradiation for advanced head and neck cancer.
|
Academic Article
|
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
|
Academic Article
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
Academic Article
|
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.
|
Academic Article
|
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
|
Academic Article
|
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
Academic Article
|
Single sample expression-anchored mechanisms predict survival in head and neck cancer.
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
|
Academic Article
|
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
|
Academic Article
|
Role of molecular markers in the management of head and neck cancers.
|
Academic Article
|
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
|
Academic Article
|
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
Searching for a standard.
|
Academic Article
|
Locally advanced non-small cell lung cancer.
|
Academic Article
|
Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
|
Academic Article
|
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
|
Academic Article
|
Esophageal cancer therapy: a decade of inertia.
|
Academic Article
|
Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
|
Academic Article
|
A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck.
|
Academic Article
|
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
|
Academic Article
|
Current treatment options for metastatic head and neck cancer.
|
Academic Article
|
Novel therapeutic targets in squamous cell carcinoma of the head and neck.
|
Academic Article
|
State-of-the-art management of locally advanced head and neck cancer.
|
Academic Article
|
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
|
Academic Article
|
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
|
Academic Article
|
Novel molecular targeted therapies for refractory thyroid cancer.
|
Academic Article
|
Pharmacoeconomic issues in head and neck oncology.
|
Academic Article
|
Forthcoming receptor tyrosine kinase inhibitors.
|
Academic Article
|
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
|
Academic Article
|
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
|
Academic Article
|
Novel targeted therapies in head and neck cancer.
|
Academic Article
|
The role of chemotherapy in locally advanced head and neck squamous cell carcinoma.
|
Academic Article
|
The future of induction chemotherapy for head and neck squamous cell carcinoma.
|
Academic Article
|
Epidermal growth factor receptor directed therapy in head and neck cancer.
|
Academic Article
|
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
Academic Article
|
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
|
Academic Article
|
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.
|
Academic Article
|
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
|
Academic Article
|
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.
|
Academic Article
|
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.
|
Academic Article
|
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
Academic Article
|
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
|
Academic Article
|
Diarrhea associated with afatinib: an oral ErbB family blocker.
|
Academic Article
|
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.
|
Academic Article
|
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
|
Academic Article
|
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
|
Academic Article
|
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
|
Academic Article
|
Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma.
|
Academic Article
|
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
|
Academic Article
|
Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy.
|
Academic Article
|
Reply to s. Chakraborty et al.
|
Academic Article
|
Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
|
Academic Article
|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
|
Academic Article
|
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
|
Academic Article
|
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
|
Academic Article
|
p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.
|
Academic Article
|
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
|
Academic Article
|
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
|
Academic Article
|
Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab.
|
Academic Article
|
Stimuli-responsive magnetic nanomicelles as multifunctional heat and cargo delivery vehicles.
|
Academic Article
|
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
|
Academic Article
|
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
|
Academic Article
|
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
|
Academic Article
|
A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis.
|
Academic Article
|
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
|
Academic Article
|
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
Academic Article
|
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
|
Academic Article
|
PI3K? is a molecular switch that controls immune suppression.
|
Academic Article
|
A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC).
|
Academic Article
|
Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
|
Academic Article
|
Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
|
Academic Article
|
Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline.
|
Academic Article
|
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
|
Academic Article
|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
|
Academic Article
|
Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association.
|
Academic Article
|
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
|
Academic Article
|
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
|
Academic Article
|
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.
|
Academic Article
|
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.
|
Academic Article
|
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
|
Academic Article
|
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
|
Academic Article
|
Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association.
|
Academic Article
|
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
|
Academic Article
|
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
|
Academic Article
|
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
|
Academic Article
|
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
|
Academic Article
|
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
|
Academic Article
|
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
|
Academic Article
|
Selection of Head and Neck Cancer Patients for Intensive Therapy.
|
Academic Article
|
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
|
Academic Article
|
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
|
Academic Article
|
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.
|
Academic Article
|
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
|
Academic Article
|
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
|
Academic Article
|
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
|
Academic Article
|
The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
|
Academic Article
|
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
|
Academic Article
|
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
|
Academic Article
|
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
|
Academic Article
|
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
|
Academic Article
|
Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.
|
Academic Article
|
Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities.
|
Academic Article
|
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
|
Academic Article
|
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
|
Academic Article
|
Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients.
|
Academic Article
|
Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.
|
Academic Article
|
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
|
Academic Article
|
Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis.
|
Academic Article
|
Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.
|
Academic Article
|
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
|
Academic Article
|
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
|
Academic Article
|
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
|
Academic Article
|
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.
|
Concept
|
Pemetrexed
|
Concept
|
RAW 264.7 Cells
|
Concept
|
Bevacizumab
|
Concept
|
Everolimus
|
Concept
|
Imatinib Mesylate
|
Concept
|
Cetuximab
|
Concept
|
Dasatinib
|
Concept
|
Erlotinib Hydrochloride
|
Concept
|
Patient Reported Outcome Measures
|
Concept
|
Autophagy-Related Protein 7
|
Concept
|
Sequestosome-1 Protein
|
Concept
|
Immunogenicity, Vaccine
|
Concept
|
MDS1 and EVI1 Complex Locus Protein
|
Concept
|
Equivalence Trials as Topic
|
Concept
|
Treatment Adherence and Compliance
|
Concept
|
Regulatory-Associated Protein of mTOR
|
Concept
|
Mechanistic Target of Rapamycin Complex 1
|
Concept
|
MCF-7 Cells
|
Concept
|
Proteasome Inhibitors
|
Concept
|
Healthy Volunteers
|
Concept
|
ErbB Receptors
|
Concept
|
Receptor, ErbB-4
|
Grant
|
Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms
|
Grant
|
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
|
Grant
|
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
|
Academic Article
|
Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
|
Academic Article
|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
|
Academic Article
|
Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy.
|
Academic Article
|
Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion.
|
Academic Article
|
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
|
Academic Article
|
Pan-Cancer Analysis of Patient Tumor Single-Cell Transcriptomes Identifies Promising Selective and Safe Chimeric Antigen Receptor Targets in Head and Neck Cancer.
|
Academic Article
|
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
|
Academic Article
|
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
|
Academic Article
|
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
|